Background: The pathophysiology of renal disease progression in autosomal-dominant polycystic kidney disease (ADPKD) involves not only cystogenesis but also endothelial dysfunction, leading to the activation of inflammatory and fibrotic pathways. This study evaluated the levels of biomarkers related to osmoregulation, immune system activation, and tubular injury in ADPKD patients with impaired or preserved renal function. Methods: This study included 26 ADPKD patients with modestly impaired renal function (estimated glomerular filtration rate [eGFR] 45–70 mL/min/1.73 m2; Group A), 26 age- and sex-matched ADPKD patients with relatively preserved renal function (eGFR >70 mL/min/1.73 m2; Group B), and 26 age- and sex-matched controls (Group C). Serum levels of copeptin, the inflammasome nucleotide-binding and oligomerization domain-like receptors pyrin domain-containing protein 3 (NLRP3), and soluble urokinase-type plasminogen activator receptor (suPAR) were measured with ELISA techniques. Results: Patients in Group A had higher levels of copeptin (median [interquartile range]: 50.44 [334.85] pg/mL), NLRP3 (5.86 [3.89] ng/mL), and suPAR (390.05 [476.53] pg/mL) compared to patients in Group B (32.38 [58.33], p = 0.042; 2.42 [1.96], p < 0.001; and 313.78 [178.85], p = 0.035, respectively) and Group C (6.75 [6.43]; 1.09 [0.56]; and 198.30 [28.53], respectively; p < 0.001 for all comparisons). Levels of all studied markers were also significantly higher in Group B patients compared to controls (p < 0.001), despite having similar eGFR. In patients with ADPKD, all studied biomarkers were correlated positively with asymmetric-dimethylarginine (ADMA) and endocan levels, and negatively with eGFR. ADMA and endocan levels were the only parameters independently associated with increased copeptin levels. Conclusions: This study showed that ADPKD patients with impaired and preserved renal function had higher copeptin, NLRP3, and suPAR levels than controls. Such findings support that cystogenesis and inflammation are associated with endothelial dysfunction, even in the early stages of ADKPD.

1.
Lanktree
MB
,
Haghighi
A
,
Guiard
E
,
Iliuta
IA
,
Song
X
,
Harris
PC
, et al.
Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing
.
J Am Soc Nephrol
.
2018
Oct
;
29
(
10
):
2593
600
.
[PubMed]
1046-6673
2.
Spithoven
EM
,
Kramer
A
,
Meijer
E
,
Orskov
B
,
Wanner
C
,
Abad
JM
, et al.
Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant.
2014
Sep
;29 Suppl 4(suppl_4):iv15-25.
3.
Ecder
T
,
Schrier
RW
.
Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease
.
Nat Rev Nephrol
.
2009
Apr
;
5
(
4
):
221
8
.
[PubMed]
1759-5061
4.
Raptis
V
,
Loutradis
C
,
Sarafidis
PA
.
Renal injury progression in autosomal dominant polycystic kidney disease: a look beyond the cysts
.
Nephrol Dial Transplant
.
2018
Nov
;
33
(
11
):
1887
95
.
[PubMed]
0931-0509
5.
Theodorakopoulou
M
,
Raptis
V
,
Loutradis
C
,
Sarafidis
P
.
Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease
.
Semin Nephrol
.
2019
Nov
;
39
(
6
):
599
612
.
[PubMed]
0270-9295
6.
Wang
X
,
Wu
Y
,
Ward
CJ
,
Harris
PC
,
Torres
VE
.
Vasopressin directly regulates cyst growth in polycystic kidney disease
.
J Am Soc Nephrol
.
2008
Jan
;
19
(
1
):
102
8
.
[PubMed]
1046-6673
7.
Raptis
V
,
Georgianos
PI
,
Sarafidis
PA
,
Sioulis
A
,
Makedou
K
,
Makedou
A
, et al.
Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease
.
Kidney Blood Press Res
.
2013
;
38
(
1
):
72
82
.
[PubMed]
1420-4096
8.
Raptis
V
,
Bakogiannis
C
,
Loutradis
C
,
Boutou
AK
,
Lampropoulou
I
,
Intzevidou
E
, et al.
Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function
.
Am J Nephrol
.
2018
;
47
(
4
):
231
8
.
[PubMed]
0250-8095
9.
Raptis
V
,
Bakogiannis
C
,
Loutradis
C
,
Boutou
AK
,
Sioulis
A
,
Balaskas
E
, et al.
Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function
.
Kidney Blood Press Res
.
2018
;
43
(
3
):
744
54
.
[PubMed]
1420-4096
10.
Meijer
E
,
Bakker
SJ
,
van der Jagt
EJ
,
Navis
G
,
de Jong
PE
,
Struck
J
, et al.
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease
.
Clin J Am Soc Nephrol
.
2011
Feb
;
6
(
2
):
361
8
.
[PubMed]
1555-9041
11.
Boertien
WE
,
Meijer
E
,
Zittema
D
,
van Dijk
MA
,
Rabelink
TJ
,
Breuning
MH
, et al.
Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease
.
Nephrol Dial Transplant
.
2012
Nov
;
27
(
11
):
4131
7
.
[PubMed]
0931-0509
12.
Boertien
WE
,
Meijer
E
,
Li
J
,
Bost
JE
,
Struck
J
,
Flessner
MF
, et al.;
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP
.
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort
.
Am J Kidney Dis
.
2013
Mar
;
61
(
3
):
420
9
.
[PubMed]
0272-6386
13.
Swanson
KV
,
Deng
M
,
Ting
JP
.
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
.
Nat Rev Immunol
.
2019
Aug
;
19
(
8
):
477
89
.
[PubMed]
1474-1733
14.
Hahm
E
,
Wei
C
,
Fernandez
I
,
Li
J
,
Tardi
NJ
,
Tracy
M
, et al.
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease
.
Nat Med
.
2017
Jan
;
23
(
1
):
100
6
.
[PubMed]
1078-8956
15.
Hayek
SS
,
Leaf
DE
,
Samman Tahhan
A
,
Raad
M
,
Sharma
S
,
Waikar
SS
, et al.
Soluble Urokinase Receptor and Acute Kidney Injury
.
N Engl J Med
.
2020
Jan
;
382
(
5
):
416
26
.
[PubMed]
0028-4793
16.
Mancia
G
,
Fagard
R
,
Narkiewicz
K
,
Redón
J
,
Zanchetti
A
,
Böhm
M
, et al.;
Task Force Members
.
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
.
J Hypertens
.
2013
Jul
;
31
(
7
):
1281
357
.
[PubMed]
0263-6352
17.
Thibonnier
M
,
Berti-Mattera
LN
,
Dulin
N
,
Conarty
DM
,
Mattera
R
.
Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors
.
Prog Brain Res
.
1998
;
119
:
147
61
.
[PubMed]
0079-6123
18.
Bankir
L
,
Bouby
N
,
Ritz
E
.
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Nat Rev Nephrol
.
2013
Apr
;
9
(
4
):
223
39
.
[PubMed]
1759-5061
19.
Torres
VE
.
Vasopressin antagonists in polycystic kidney disease
.
Kidney Int
.
2005
Nov
;
68
(
5
):
2405
18
.
[PubMed]
0085-2538
20.
Torres
VE
,
Chapman
AB
,
Devuyst
O
,
Gansevoort
RT
,
Grantham
JJ
,
Higashihara
E
, et al.;
TEMPO 3:4 Trial Investigators
.
Tolvaptan in patients with autosomal dominant polycystic kidney disease
.
N Engl J Med
.
2012
Dec
;
367
(
25
):
2407
18
.
[PubMed]
0028-4793
21.
Torres
VE
,
Chapman
AB
,
Devuyst
O
,
Gansevoort
RT
,
Perrone
RD
,
Koch
G
, et al.;
REPRISE Trial Investigators
.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
.
N Engl J Med
.
2017
Nov
;
377
(
20
):
1930
42
.
[PubMed]
0028-4793
22.
Zittema
D
,
van den Berg
E
,
Meijer
E
,
Boertien
WE
,
Muller Kobold
AC
,
Franssen
CF
, et al.
Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients
.
Clin J Am Soc Nephrol
.
2014
Sep
;
9
(
9
):
1553
62
.
[PubMed]
1555-9041
23.
Corradi
V
,
Martino
F
,
Gastaldon
F
,
Scalzotto
E
,
Caprara
C
,
Fortunato
A
, et al.
Copeptin levels and kidney function in ADPKD: case-control study
.
Clin Nephrol
.
2016
Sep
;
86
(
9
):
147
53
.
[PubMed]
0301-0430
24.
Magistroni
R
,
Mangolini
A
,
Guzzo
S
,
Testa
F
,
Rapanà
MR
,
Mignani
R
, et al.
TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes
.
BMC Nephrol
.
2019
Sep
;
20
(
1
):
355
.
[PubMed]
1471-2369
25.
Lv
L
,
Wang
F
,
Wu
L
,
Wang
JW
,
Cui
Z
,
Hayek
SS
, et al.
Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease
.
Nephrol Dial Transplant
.
2018
Aug
.
[PubMed]
0931-0509
26.
Hayek
SS
,
Landsittel
DP
,
Wei
C
,
Zeier
M
,
Yu
AS
,
Torres
VE
, et al.
Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease
.
J Am Soc Nephrol
.
2019
Jul
;
30
(
7
):
1305
13
.
[PubMed]
1046-6673
27.
Levey
AS
,
Stevens
LA
,
Schmid
CH
,
Zhang
YL
,
Castro
AF
 3rd
,
Feldman
HI
, et al.;
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
.
A new equation to estimate glomerular filtration rate
.
Ann Intern Med
.
2009
May
;
150
(
9
):
604
12
.
[PubMed]
0003-4819
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.